nausea [SEP] ne with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with eith

Nausea [SEP] An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and moti


headache [SEP] acalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramin

Headache [SEP] The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACH


L-DOPA [SEP] Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.

Levodopa [SEP] The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can b


dyskinesia [SEP] nalysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.

Dyskinesia, Drug-Induced [SEP] Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or


L-DOPA [SEP] L-DOPA-induced dyskinesia (LID) is among the motor complications that


dyskinesia [SEP] L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson'


LID [SEP] L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's dis


Parkinson's disease [SEP] dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA. To this

Parkinson Disease [SEP] A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency


PD [SEP] mong the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA. To this day,


6-hydroxydopamine [SEP] rotein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocrip

Oxidopamine [SEP] A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in th


bromocriptine [SEP] ydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass s

Bromocriptine [SEP] A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.


allergic reactions [SEP] Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.

Drug Hypersensitivity [SEP] Immunologically mediated adverse reactions to medicinal substances used legally or illegally.


corticosteroids [SEP] Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.

Adrenal Cortex Hormones [SEP]


paramethasone [SEP] Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described. A few mi

Paramethasone [SEP] A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in


dexamethasone [SEP] wo patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described. A few minutes after administration o

Dexamethasone [SEP] An anti-inflammatory 9-fluoro-glucocorticoid.


urticaria [SEP] A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1). The purpose

Urticaria [SEP] A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability


conjunctivitis [SEP] n of the drugs, they presented urticaria (patients 1 and 2) and conjunctivitis (patient 1). The purpose of our study was to determine the caus

Conjunctivitis [SEP]


corticosteroids [SEP] nations and skin, oral and parenteral challenges with different corticosteroids and ELISA tests were performed. In the two patients, skin and E

Adrenal Cortex Hormones [SEP]


hypersensitivity [SEP] nts. Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolera


allergy [SEP] erstood. To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.


Valproic acid [SEP] Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 20

Valproic Acid [SEP] A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not


encephalopathy [SEP] Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect assoc

Brain Diseases [SEP] Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This


VPA [SEP] cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.


Valproic acid [SEP] Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually wel


VPA [SEP] Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tol


pancreatitis [SEP] omplications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-in

Pancreatitis [SEP] INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde


bone marrow suppression [SEP] ay occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy. The

Bone Marrow Diseases [SEP]


hepatotoxicity [SEP] haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy. The typical signs of VPA-induce

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


encephalopathy [SEP]  marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy. The typical signs of VPA-induced encephalopathy are impaired c


impaired consciousness [SEP] phalopathy. The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure fre

Consciousness Disorders [SEP] Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respon


seizure [SEP] nsciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia. There is still no pr

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


hyperammonemia [SEP] ackground slowing, increased seizure frequency, with or without hyperammonemia. There is still no proof of causative effect of VPA in patients

Hyperammonemia [SEP] Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.


Haemolytic-uraemic syndrome [SEP] Haemolytic-uraemic syndrome after treatment with metronidazole.

Hemolytic-Uremic Syndrome [SEP] A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by


metronidazole [SEP] Haemolytic-uraemic syndrome after treatment with metronidazole.

Metronidazole [SEP] A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFE


haemolytic-uraemic syndrome [SEP] scribes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole. These children were older a


metronidazole [SEP]  developed the haemolytic-uraemic syndrome after treatment with metronidazole. These children were older and were more likely to have undergo


sensorineural hearing loss [SEP] Risk factors of sensorineural hearing loss in preterm infants.

Hearing Loss, Sensorineural [SEP] Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round


sensorineural hearing loss [SEP] , 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss. Perinatal risk factors of infants with hearing loss were compa


hearing loss [SEP] 1.46%) developed severe progressive and bilateral sensorineural hearing loss. Perinatal risk factors of infants with hearing loss were compa

Hearing Loss [SEP] A general term for the complete or partial loss of the ability to hear from one or both ears.


Ototoxicity [SEP] earing loss with a higher incidence of perinatal complications. Ototoxicity appeared closely related to a prolonged administration and high

Hearing Disorders [SEP] Conditions that impair the transmission of auditory impulses and information from the level of the ear to the temporal cortices,


ototoxic [SEP]  related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide. Finally, we


aminoglycosides [SEP] istration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide. Finally, we strongly recommend to prospectively

Aminoglycosides [SEP] Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTIC


furosemide [SEP]  total dose of ototoxic drugs, particularly aminoglycosides and furosemide. Finally, we strongly recommend to prospectively and regularly

Furosemide [SEP] A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFF


cimetidine [SEP] Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.

Cimetidine [SEP] A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacol


confusion [SEP]  clinical studies in patients with cimetidine-associated mental confusion.

Confusion [SEP] A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.


cimetidine [SEP] 15 cases of cimetidine-associated mental confusion have been reported. In order that t


confusion [SEP] 15 cases of cimetidine-associated mental confusion have been reported. In order that this syndrome might be invest


liver dysfunction [SEP] moderate to severe changes. These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations

Liver Diseases [SEP] Pathological processes of the LIVER.


histamine [SEP] raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system. Patients likely to

Histamine [SEP] An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of br


hepatic dysfunction [SEP] tions and mental confusion are those with both severe renal and hepatic dysfunction. They should be closely observed and should be given reduced do


extrahepatic cholestasis [SEP] ed hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.

Cholestasis, Extrahepatic [SEP] Impairment of bile flow in the large BILE DUCTS by mechanical obstruction or stricture due to benign or malignant processes.


cholestasis [SEP] role in bile formation. Although hepatocyte TJs are impaired in cholestasis, attempts to localize the precise site of hepatocyte TJ damage

Cholestasis [SEP] Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EX


intrahepatic cholestasis [SEP] correlate with paracellular permeability. We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasi

Cholestasis, Intrahepatic [SEP] Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPA


ethinyl estradiol [SEP] permeability. We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligati

Ethinyl Estradiol [SEP] A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orall


EE [SEP] ed rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (


extrahepatic cholestasis [SEP] ntrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of


beta-thalassemic [SEP] Long term audiological evaluation of beta-thalassemic patients.

beta-Thalassemia [SEP] A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis i


hearing loss [SEP] was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major. METHO


beta-thalassemia [SEP] e progression of hearing loss in children and young adults with beta-thalassemia major. METHODS: One hundred and four (104) patients aged 6-35 y


desferrioxamine [SEP] g a mean hemoglobin level of 9.5 gr/dl. Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg

Deferoxamine [SEP] Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in th


DFO [SEP] in level of 9.5 gr/dl. Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6


sensorineural hearing loss [SEP] l, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral. No ototoxic factor, oth


SNHL [SEP] 0.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral. No ototoxic factor, other tha


ototoxic [SEP] ineural hearing loss (SNHL), either unilateral or bilateral. No ototoxic factor, other than DFO, was present in any of the patients. Pat


hearing impairment [SEP] are indicative of DFO's contributing role in the development of hearing impairment. Regular audiologic evaluation is imperative in all thalassemic


thalassemic [SEP]  impairment. Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment

Thalassemia [SEP] A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. Ther


enalapril [SEP] Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with co

Enalapril [SEP] One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension.


prazosin [SEP] esign and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive hear

Prazosin [SEP] A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEAS


congestive heart failure [SEP] il and prazosin in the initial treatment phase of patients with congestive heart failure.

Heart Failure [SEP] A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Hear


angiotensin converting enzyme (ACE) inhibitors [SEP] Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart

Angiotensin-Converting Enzyme Inhibitors [SEP] A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect


congestive heart failure [SEP] (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of tr


hypotension [SEP] ment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally be

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


ACE inhibitor [SEP] t, have occasionally been reported. To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial


enalapril [SEP] onally been reported. To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was design


prazosin [SEP] afety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and s


azidothymidine [SEP] ntagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.

Zidovudine [SEP] A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modific


anemia [SEP] leukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.

Anemia [SEP] A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.


Azidothymidine [SEP] Azidothymidine (AZT)-induced anemia in mice can be reversed by the administrat


AZT [SEP] Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration o


anemia [SEP] Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusi


thymidine [SEP] Azidothymidine (AZT)-induced anemia in mice can be reversed by the administrat

Thymidine [SEP]


Na [SEP] Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.

Sodium [SEP] A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.


Ca [SEP] Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


Na [SEP] The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and t


Ca [SEP] e effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the nega


verapamil [SEP] the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria. Basal frequency (BF) e

Verapamil [SEP] A calcium channel blocker that is a class IV anti-arrhythmia agent.


bradycardia [SEP] negative chronotropic effects were BF-dependent. Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa. Inde

Bradycardia [SEP] Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. Th


Sodium [SEP] Sodium status influences chronic amphotericin B nephrotoxicity in rats


amphotericin B [SEP] Sodium status influences chronic amphotericin B nephrotoxicity in rats.

Amphotericin B [SEP] Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.


nephrotoxicity [SEP] Sodium status influences chronic amphotericin B nephrotoxicity in rats.

Kidney Diseases [SEP] Pathological processes of the KIDNEY or its component tissues.


nephrotoxic [SEP] The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally


amphotericin B [SEP] The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been invest


creatinine [SEP] lt-loaded rats. In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.

Creatinine [SEP]


sodium [SEP] for 2 weeks and was decreased by 43% at week 3. All rats in the sodium-depleted group had histopathological evidence of patchy tubular


inferior colliculus lesion [SEP] Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance fin

Brain Diseases [SEP] Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This


metronidazole [SEP] Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusio

Metronidazole [SEP] A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFE


encephalopathy [SEP] Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid at


inferior colliculus lesions [SEP] OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffus


metronidazole [SEP] E: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imag


encephalopathy [SEP] reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid att


infection [SEP] l dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs. Initial brain magnetic resonance imaging (MR

Infection [SEP] Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.


callosal lesion [SEP]  follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted. CONCLUSIONS: Reversible inferior colliculus lesions


morphine [SEP] Comparison of the respiratory effects of i.v. infusions of morphine and regional analgesia by extradural block.

Morphine [SEP] The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central


apnoea [SEP] The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.

Apnea [SEP] A transient absence of spontaneous respiration.


morphine [SEP] d between five patients receiving a continuous i.v. infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradu


bupivacaine [SEP] ve patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surg

Bupivacaine [SEP] A widely used local anesthetic agent.


carbon dioxide [SEP] dominal surgery. Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, a

Carbon Dioxide [SEP] A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals.


central apnoea [SEP] ter ambulatory monitor. Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had

Sleep Apnea, Central [SEP] A condition associated with multiple episodes of sleep apnea which are distinguished from obstructive sleep apnea (SLEEP APNEA,


tachyarrhythmias [SEP] o had a morphine infusion. There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0

Tachycardia [SEP] Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturba


ventricular ectopic beats [SEP] o a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.

Ventricular Premature Complexes [SEP] A type of cardiac arrhythmia with premature contractions of the HEART VENTRICLES. It is characterized by the premature QRS compl


epileptic [SEP] Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.

Epilepsy [SEP] A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuron


phenytoin [SEP] sonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.

Phenytoin [SEP] An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mec


overdosages [SEP] lumetry of the cerebellum in epileptic patients after phenytoin overdosages.

Drug Overdose [SEP] Accidental or deliberate use of a medication or street drug in excess of normal dosage.


phenytoin [SEP] The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienc


cerebellar atrophy [SEP] s to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication. Five fem

Cerebellar Diseases [SEP] Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysm


seizure [SEP] g linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar vo

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


overdosage [SEP] d a correlation of these parameters. We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unl


cerebellar disorders [SEP] e cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.


myocardial damage [SEP] Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relations

Cardiomyopathies [SEP] A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classifi


doxorubicin [SEP] diac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echoca

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


cardiomyopathy [SEP] T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histolo


myocardial cell injury [SEP]  have been shown to be highly sensitive and specific markers of myocardial cell injury. We investigated the diagnostic value of cTnI and cTnT for the


myocardial damage [SEP] ated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and


doxorubicin [SEP] d cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship


DOX [SEP] e diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship betwe


cardiomyopathy [SEP] f myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT


cardiac disorders [SEP] lationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in

Heart Diseases [SEP] Pathological conditions involving the HEART including its structural and functional abnormalities.


toxicity [SEP] . RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period. End-diastolic (ED) and end-systolic (

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


fibrosis [SEP] led significant slight degrees of perivascular and interstitial fibrosis. In 7 of the 18 rats, degeneration and myocyte vacuolisation we

Fibrosis [SEP] Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other


ischemic injury [SEP] ers/BW and histological findings. CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect m

Myocardial Ischemia [SEP] A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may


cardiotoxicity [SEP] be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


pain [SEP] Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ tr

Pain [SEP] An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.


pain [SEP] Bone pain after transplantation is a frequent complication that can be ca


bone marrow [SEP] take of the foot bones. Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones. Pain was not explained by other di

Bone Marrow Diseases [SEP]


oedema [SEP] foot bones. Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones. Pain was not explained by other diseases

Edema [SEP] Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.


Pain [SEP] e imaging demonstrated bone marrow oedema in the painful bones. Pain was not explained by other diseases causing foot pain, like ref


reflex sympathetic dystrophy [SEP] ain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascu

Reflex Sympathetic Dystrophy [SEP] A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone


polyneuropathy [SEP]  diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, in

Polyneuropathies [SEP] Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral dist


Morton's neuralgia [SEP] g foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudicat

Neuralgia [SEP] Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.


gout [SEP] flex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, o

Gout [SEP] Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and ar


osteoporosis [SEP] ympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foo

Osteoporosis [SEP] Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two m


avascular necrosis [SEP] trophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stres

Osteonecrosis [SEP] Death of a bone or part of a bone, either atraumatic or posttraumatic.


intermittent claudication [SEP] hy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparat

Intermittent Claudication [SEP] A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and wea


foot deformities [SEP] sis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cy

Foot Deformities [SEP] Alterations or deviations from normal shape or size which result in a disfigurement of the foot.


stress fractures [SEP] rosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tac

Fractures, Stress [SEP] Fractures due to the strain caused by repetitive exercise. They are thought to arise from a combination of MUSCLE FATIGUE and bo


hyperparathyroidism [SEP] audication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and

Hyperparathyroidism [SEP] A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It i


cyclosporine [SEP] es, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium

Cyclosporine [SEP] A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes.


tacrolimus [SEP] res, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blocker

Tacrolimus [SEP] A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity


calcium [SEP] osporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain. The Calcineurin-inhibit

Calcium [SEP] A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic sym


propofol [SEP] The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3

Propofol [SEP] An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very shor


ephedrine [SEP] The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).

Ephedrine [SEP] A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may als


propofol [SEP] The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients. We investigated th


ephedrine [SEP] vestigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response. The ha


hypotensive [SEP] different doses of ephedrine to propofol in order to obtund the hypotensive response. The haemodynamic effects of adding 15, 20 or 25 mg of

Hypotension [SEP] Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DI


tachycardia [SEP] se to propofol at all doses used in this study. However, marked tachycardia associated with the use of ephedrine in combination with propof

Tachycardia [SEP] Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturba


myocardial ischemia [SEP] dividual patients. Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of t

Myocardial Ischemia [SEP] A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may


Neurotoxicity [SEP] Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases re

Neurotoxicity Syndromes [SEP] Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method


halogenated hydroxyquinolines [SEP] Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.

Hydroxyquinolines [SEP] The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti


neurotoxic [SEP] An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outsid


halogenated hydroxyquinolines [SEP] s is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan. In 80 cases insufficient informati


clioquinol [SEP] quate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquin

Clioquinol [SEP] A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal


neurological disturbance [SEP] n 42 and possible in 69 cases. In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related

Nervous System Diseases [SEP] Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, periph


encephalopathy [SEP] s the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol o

Brain Diseases [SEP] Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This


optic atrophy [SEP] ommon manifestation, observed in 15 further cases, was isolated optic atrophy. This was most frequently found in children, many of whom had r

Optic Atrophy [SEP] Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibe


acrodermatitis enteropathica [SEP] children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of myelopathy, visual di

Acrodermatitis enteropathica [SEP]


myelopathy [SEP] matitis enteropathica. In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most com

Spinal Cord Diseases [SEP] Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimening


visual disturbance [SEP] ropathica. In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation. I

Vision Disorders [SEP] Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peri


peripheral neuropathy [SEP] ing cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation. Isolated myelopathy or perip

Peripheral Nervous System Diseases [SEP] Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, pl


optic neuropathy [SEP]  display more side effects. The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken great

Optic Nerve Diseases [SEP] Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component o


Epileptic seizures [SEP] Epileptic seizures following cortical application of fibrin sealants containing tr

Epilepsy [SEP] A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuron


tranexamic acid [SEP] es following cortical application of fibrin sealants containing tranexamic acid in rats.

Tranexamic Acid [SEP] Antifibrinolytic hemostatic used in severe hemorrhage.


tranexamic acid [SEP]  inhibitor. Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin. Howe


tAMCA [SEP] tly, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin. However, tA


epileptic seizures [SEP] bstitutes for aprotinin. However, tAMCA has been shown to cause epileptic seizures. We wanted to study whether tAMCA retains its convulsive action


convulsive [SEP] pileptic seizures. We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS. METHOD: FS containing aprotin

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


seizures [SEP] for aprotinin. However, tAMCA has been shown to cause epileptic seizures. We wanted to study whether tAMCA retains its convulsive action


generalized seizures [SEP] entration of tAMCA. Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMC


Tranexamic acid [SEP] protinin did not evoke any paroxysmal activity. INTERPRETATION: Tranexamic acid retains its convulsive action within FS. Thus, use of FS contai


sugar dependency [SEP] A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetam

Substance-Related Disorders [SEP] Disorders related to substance abuse.


behavioral cross-sensitization [SEP] A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.

Hyperkinesis [SEP] Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.


amphetamine [SEP] pendency causes behavioral cross-sensitization to a low dose of amphetamine.

Amphetamine [SEP] A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blockin


drug dependency [SEP] duces a state with neurochemical and behavioral similarities to drug dependency. The present study examined whether female rats on various regi


behavioral cross-sensitization [SEP] ther female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine. After a 30-min baseline measure o


amphetamine [SEP] cess would show behavioral cross-sensitization to a low dose of amphetamine. After a 30-min baseline measure of locomotor activity (day 0),


sucrose [SEP]  cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset

Sucrose [SEP] A nonreducing disaccharide composed of GLUCOSE and FRUCTOSE linked via their anomeric carbons. It is obtained commercially from


hyperactive [SEP] . The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (a


dopamine [SEP] ity to amphetamine, possibly due to a lasting alteration in the dopamine system.

Dopamine [SEP] One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and


D-penicillamine [SEP] D-penicillamine-induced angiopathy in rats. The effect of high dose D-penicilla

Penicillamine [SEP] 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic a


angiopathy [SEP] D-penicillamine-induced angiopathy in rats. The effect of high dose D-penicillamine treatment on a

Aortic Diseases [SEP] Pathological processes involving any part of the AORTA.


D-penicillamine [SEP] Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days. Pair fed rats served a


D-pen [SEP] Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days. Pair fed rat


hyaluronate [SEP] er which may be caused by a steric exclusion effect of abundant hyaluronate. The endothelial ultrastructure was unaffected by D-pen, and no

Hyaluronic Acid [SEP] A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is f


anthracycline [SEP] Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.

Anthracyclines [SEP] Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daun


cardiotoxicity [SEP] ain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.

Cardiotoxicity [SEP] Damage to the heart or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY;


Anthracyclines [SEP] Anthracyclines are effective antineoplastic drugs, but they frequently cause d


cardiotoxicity [SEP] ve antineoplastic drugs, but they frequently cause dose-related cardiotoxicity. The cardiotoxicity of conventional anthracycline therapy highl


anthracycline [SEP] dose-related cardiotoxicity. The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly


cardiac dysfunction [SEP] for methods that are highly sensitive and capable of predicting cardiac dysfunction. We measured the plasma level of brain natriuretic peptide (BNP

Heart Diseases [SEP] Pathological conditions involving the HEART including its structural and functional abnormalities.


acute leukemia [SEP] icator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen. Thirteen

Leukemia, Myeloid, Acute [SEP] Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that


daunorubicin [SEP] d cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen. Thirteen patients with acute leukemia

Daunorubicin [SEP] A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of L


DNR [SEP] ty in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen. Thirteen patients with acute leukemia were


congestive heart failure [SEP]  the time of radionuclide angiography. Three patients developed congestive heart failure after the completion of chemotherapy. Five patients were diagno

Heart Failure [SEP] A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Hear


heart failure [SEP] f radionuclide angiography. Three patients developed congestive heart failure after the completion of chemotherapy. Five patients were diagno


birth defects [SEP] Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.

Abnormalities, Drug-Induced [SEP] Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is in


Birth Defects [SEP] cation use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.


birth defects [SEP]  the association between antibacterial medications and selected birth defects. DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite


birth defect [SEP]  the association between antibacterial medications and selected birth defects. DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisit


Sulfonamides [SEP] als increased during pregnancy, peaking during the third month. Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95%

Sulfonamides [SEP] A group of compounds that contain the structure SO2NH2.


anencephaly [SEP] aking during the third month. Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8

Anencephaly [SEP] A malformation of the nervous system caused by failure of the anterior neuropore to close. Infants are born with intact spinal c


hypoplastic left heart syndrome [SEP] djusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2

Hypoplastic Left Heart Syndrome [SEP] A condition caused by underdevelopment of the whole left half of the heart. It is characterized by hypoplasia of the left cardia


coarctation of the aorta [SEP] , hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% C

Aortic Coarctation [SEP] A birth defect characterized by the narrowing of the AORTA that can be of varying degree and at any point from the transverse ar


choanal atresia [SEP] .3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR

Choanal Atresia [SEP] A congenital abnormality that is characterized by a blocked CHOANAE, the opening between the nose and the NASOPHARYNX. Blockage


transverse limb deficiency [SEP] 5% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2

Limb Deformities, Congenital [SEP] Congenital structural deformities of the upper and lower extremities collectively or unspecified.


diaphragmatic hernia [SEP] ), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated w

Hernia, Diaphragmatic [SEP] Protrusion of abdominal structures into the THORAX as a result of congenital or traumatic defects in the respiratory DIAPHRAGM.


Nitrofurantoins [SEP] .0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7;

Nitrofurantoin [SEP] A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antib


anophthalmia [SEP] R = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic le

Anophthalmos [SEP] Congenital absence of the eye or eyes.


microphthalmos [SEP]  1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome

Microphthalmos [SEP] Congenital or developmental anomaly in which the eyeballs are abnormally small.


atrial septal defects [SEP] , hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (

Heart Septal Defects, Atrial [SEP] Developmental abnormalities in any portion of the ATRIAL SEPTUM resulting in abnormal communications between the two upper chamb


cleft lip [SEP] 9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacte

Cleft Lip [SEP] Congenital defect in the upper lip where the maxillary prominence fails to merge with the merged medial nasal prominences. It is


cleft palate [SEP] septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that s

Cleft Palate [SEP] Congenital fissure of the soft and/or hard palate, due to faulty fusion.


erythromycins [SEP] ). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect),

Erythromycin [SEP] A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active componen


penicillins [SEP] ts that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect

Penicillins [SEP] A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nuc


cephalosporins [SEP] ons included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect). CONCLUSIONS: Reassuringl

Cephalosporins [SEP] A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moie


quinolones [SEP] efects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect). CONCLUSIONS: Reassuringly, penicillins, erythromyci

Quinolones [SEP] A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.


nitrofurantoins [SEP] , were not associated with many birth defects. Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need f


neoplasms [SEP] Incidence of neoplasms in patients with rheumatoid arthritis exposed to different trea

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


rheumatoid arthritis [SEP] Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.

Arthritis, Rheumatoid [SEP] A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular stru


rheumatoid arthritis [SEP] d during the last 30 years in treatment of patients with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil


cyclophosphamide [SEP] s with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine anal

Cyclophosphamide [SEP] Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to fo


chlorambucil [SEP] oid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methot

Chlorambucil [SEP] A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Alth


alkylating agents [SEP]  The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid

Alkylating Agents [SEP] Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper func


azathioprine [SEP] used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). Ther

Azathioprine [SEP] An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthr


purine [SEP] phosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evi

Purines [SEP] A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADE


methotrexate [SEP] mbucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosu

Methotrexate [SEP] An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and pre


folic acid [SEP] ting agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive dr

Folic Acid [SEP] A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in


synovitis [SEP] re is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is sto

Synovitis [SEP] Inflammation of a synovial membrane. It is usually painful, particularly on motion, and is characterized by a fluctuating swelli


acute nonlymphocytic leukemia [SEP] with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated wit

Leukemia, Myeloid, Acute [SEP] Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that


non-Hodgkin's lymphoma [SEP]  agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of carcinoma of th

Lymphoma, Non-Hodgkin [SEP] Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to


Cyclophosphamide [SEP]  are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of carcinoma of the bladder. There h


carcinoma of the bladder [SEP] gkin's lymphoma. Cyclophosphamide therapy increases the risk of carcinoma of the bladder. There have been several long-term studies of patients with rhe

Urinary Bladder Neoplasms [SEP] Tumors or cancer of the URINARY BLADDER.


carcinoma [SEP] gkin's lymphoma. Cyclophosphamide therapy increases the risk of carcinoma of the bladder. There have been several long-term studies of pa

Carcinoma [SEP] A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It i


cancers [SEP] ne and cyclophosphamide and the incidence of most of the common cancers is not increased. Data on the possible increased risk of malign


malignancy [SEP] ancers is not increased. Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until fu


hepatic injury [SEP] Patterns of hepatic injury induced by methyldopa.

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


methyldopa [SEP] Patterns of hepatic injury induced by methyldopa.

Methyldopa [SEP] An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an ant


liver disease [SEP] Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977. Illness

Liver Diseases [SEP] Pathological processes of the LIVER.


methyldopa [SEP] Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977. Illness occurred within 1--9 w


Jaundice [SEP]  13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malai

Jaundice [SEP] A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA


hepatomegaly [SEP]  and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and

Hepatomegaly [SEP] Enlargement of the liver.


anorexia [SEP] h tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain,

Anorexia [SEP] The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of t


nausea [SEP] epatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an

Nausea [SEP] An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and moti


vomiting [SEP] , usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable fi

Vomiting [SEP] The forcible expulsion of the contents of the STOMACH through the MOUTH.


abdominal pain [SEP] laise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients. Biochemical liver f

Abdominal Pain [SEP] Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue inju


necrosis [SEP] ents. Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injur

Necrosis [SEP] The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrol


hepatic injury [SEP] ular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepat


fatty change [SEP] l evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.

Fatty Liver [SEP] Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usua


massive hepatic necrosis [SEP] h ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis. Most patients showed moderate to severe acute hepatitis or chr

Massive Hepatic Necrosis [SEP] Extensive and rapid death of parenchymal cells in the LIVER, often due to exposure to toxic materials. It is characterized by a


acute hepatitis [SEP] ssive hepatic necrosis. Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The dr

Liver Failure, Acute [SEP] A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of H


chronic active hepatitis [SEP] sis. Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The drug was withdrawn on presenta

Hepatitis, Chronic [SEP] INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and


cholestasis [SEP] ere acute hepatitis or chronic active hepatitis with associated cholestasis. The drug was withdrawn on presentation to hospital in 11 patie

Cholestasis [SEP] Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EX


hepatic failure [SEP] linical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showe

Liver Failure [SEP] Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum leve


fulminant hepatitis [SEP] f several months. The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior


hepatitis [SEP] hepatic necrosis. Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The dr


hepatic dysfunction [SEP] and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of r


paclitaxel [SEP] A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers:

Paclitaxel [SEP] A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized


cisplatin [SEP] A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary re

Cisplatin [SEP] An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and inter


head and neck cancers [SEP] II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.

Head and Neck Neoplasms [SEP] Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus.


head and neck carcinomas [SEP] Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy. Prel


paclitaxel [SEP]  of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a


Taxol [SEP] rn Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% re


head and neck cancer [SEP] y, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used success


cisplatin [SEP]  rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly im


ovarian cancer [SEP] ully and has significantly improved median response duration in ovarian cancer patients. We initiated a phase I/II trial to determine the resp

Ovarian Neoplasms [SEP] Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin


toxicity [SEP] . We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplat

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


head and neck carcinoma [SEP] Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy. Pre


tumor [SEP] ars and good performance status have entered the trial. Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx,

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


Alopecia [SEP] erved in patients who had achieved clinical complete responses. Alopecia, paresthesias, and arthralgias/myalgias have occurred frequentl

Alopecia [SEP] Absence of hair from areas where it is normally present.


paresthesias [SEP] atients who had achieved clinical complete responses. Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with on

Paresthesia [SEP] Subjective cutaneous sensations (e.g., cold, warmth, tingling, pressure, etc.) that are experienced spontaneously in the absence


arthralgias [SEP] hieved clinical complete responses. Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a gr

Arthralgia [SEP] Pain in the joint.


myalgias [SEP] cal complete responses. Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 mya

Myalgia [SEP] Painful sensation in the muscles.


myalgia [SEP] cal complete responses. Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 my


Paclitaxel [SEP] de 1 or 2. No dose-limiting hematologic toxicity has been seen. Paclitaxel/cisplatin is an effective first-line regimen for locoregionally


4'-0-tetrahydropyranyladriamycin [SEP] A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics.

pirarubicin [SEP]


4'-0-tetrahydropyranyladriamycin [SEP] A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance statu

pirarubicin [SEP]


Pirarubicin [SEP] udy of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refrac

pirarubicin [SEP]


tumors [SEP]  done in 55 patients in good performance status with refractory tumors. Twenty-six had minimal prior therapy (good risk), 23 had exten


hepatic dysfunction [SEP] d extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction. A total of 167 courses at doses of 15 to 70 mg/m2 were evaluab

Liver Diseases [SEP] Pathological processes of the LIVER.


granulocytopenia [SEP] /m2. The dose-limiting toxic effect was transient noncumulative granulocytopenia. Granulocyte nadir was on day 14 (range, 4-22). Less frequent t

Agranulocytosis [SEP] A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).


thrombocytopenia [SEP] s on day 14 (range, 4-22). Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelo

Thrombocytopenia [SEP] A subnormal level of BLOOD PLATELETS.


anemia [SEP] , 4-22). Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppress

Anemia [SEP] A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.


nausea [SEP]  Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was

Nausea [SEP] An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and moti


alopecia [SEP] t toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patient


phlebitis [SEP] fects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepa

Phlebitis [SEP] Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).


mucositis [SEP] thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction

Mucositis [SEP] An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vas


Myelosuppression [SEP] penia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic

Bone Marrow Diseases [SEP]


Adriamycinol [SEP] - 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol

adriamycinol [SEP]


doxorubicin [SEP] d total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the meta

Doxorubicin [SEP] Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.


adriamycinone [SEP] ance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detecte

adriamycin aglycone [SEP]


tetrahydropyranyladriamycinol [SEP] + 39.3 l/hour/m2. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxor

pirarubicin [SEP]


mesothelioma [SEP] t 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma. The recommended star

Mesothelioma [SEP] A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some region


leiomyosarcoma [SEP]  less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma. The recommended starting dose for Ph

Leiomyosarcoma [SEP] A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera


basal cell carcinoma [SEP] to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma. The recommended starting dose for Phase II trials is 60 mg/m2

Carcinoma, Basal Cell [SEP] A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is d


gamma-hexachlorocyclohexane [SEP] Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.

Lindane [SEP] An organochlorine insecticide that has been used as a pediculicide and a scabicide. It has been shown to cause cancer.


lindane [SEP] Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.


seizures [SEP] ma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


Gamma-hexachlorocyclohexane [SEP] Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane,


gamma-HCH [SEP] Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been sh


lindane [SEP] clohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazo


seizure [SEP] gredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-


PTZ [SEP] as been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase thresh

Pentylenetetrazole [SEP] A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-comp


seizures [SEP] e to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981). In this


Seizure [SEP] hile 24 h after gamma-HCH a differential response was observed. Seizure activity due to PTZ and picrotoxin (PTX) was significantly decr


picrotoxin [SEP] erential response was observed. Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity du

Picrotoxin [SEP] A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated c


PTX [SEP] ponse was observed. Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to


3-mercaptopropionic acid [SEP] ) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carbol

3-Mercaptopropionic Acid [SEP] An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing co


MPA [SEP] sed; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3


bicuculline [SEP] owever, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (

Bicuculline [SEP] An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors


BCC [SEP] re activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM)


methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate [SEP] ivity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control. In

methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate [SEP]


DMCM [SEP]  (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control. In vitro,


strychnine [SEP] thyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control. In vitro, gamma-HCH, pent

Strychnine [SEP] An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsan


STR [SEP] ethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control. In vitro, gamma-HCH, pentylene


pentylenetetrazol [SEP] nine (STR) was not different from control. In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse w


3H-TBOB [SEP] mma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and

tert-butylbicyclo-2-benzoate [SEP]


t-butyl bicyclo-orthobenzoate [SEP] ively. MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron. The pharmacological c

tert-butylbicyclo-2-benzoate [SEP]


GABA [SEP] he decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.

gamma-Aminobutyric Acid [SEP] The most common inhibitory neurotransmitter in the central nervous system.


orbital toxicity [SEP] Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent gliob

Orbital Diseases [SEP] Diseases of the bony orbit and contents except the eyeball.


carboplatin [SEP] ere ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.

Carboplatin [SEP] An organoplatinum compound that possesses antineoplastic activity.


glioblastomas [SEP] icity after intracarotid injection of carboplatin for recurrent glioblastomas.

Glioblastoma [SEP] A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necr


Glioblastoma [SEP] BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adultho


malignant tumor [SEP] BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood. With current trea

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


glioblastoma [SEP] ts is limited to approximately 1 year. Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added t


carboplatin [SEP] on of carcinostatics added to the treatment regimen. Generally, carboplatin is said to have milder side effects than cisplatin, whose ocula


cisplatin [SEP] Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known. However, we

Cisplatin [SEP] An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and inter


orbital toxicity [SEP] id to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular


glioblastomas [SEP] received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual dis


visual disturbance in the ipsilateral eye [SEP] oblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings

Vision Disorders [SEP] Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peri


toxicity [SEP] ve milder side effects than cisplatin, whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


glycerin [SEP]  treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection. Although the intraocular pressu

Glycerol [SEP] A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pha


glaucoma [SEP] ular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema an

Glaucoma [SEP] An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the int


ocular pain [SEP]  caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detach

Eye Pain [SEP] A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.


papilledema [SEP] osure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally

Papilledema [SEP] Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of


retinal detachment [SEP] nd ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse choriore

Retinal Detachment [SEP] Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonl


chorioretinal atrophy [SEP] tachment continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was

Sveinsson Chorioretinal Atrophy [SEP]


optic atrophy [SEP] eks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost. CONCLUSION: W

Optic Atrophy [SEP] Atrophy of the optic disk which may be congenital or acquired. This condition indicates a deficiency in the number of nerve fibe


ocular toxicity [SEP] on of carboplatin, we must be aware of its potentially blinding ocular toxicity. It is recommended that further studies and investigations are

Eye Diseases [SEP] Diseases affecting the eye.


amsacrine [SEP] Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

Amsacrine [SEP] Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemia


CI-921 [SEP] Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

asulacrine [SEP]


NSC 343499 [SEP] Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

asulacrine [SEP]


non-small cell lung cancer [SEP] Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

Carcinoma, Non-Small-Cell Lung [SEP] A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENO


CI-921 [SEP] CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]ami

asulacrine [SEP]


NSC 343499 [SEP] CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dim

asulacrine [SEP]


9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide [SEP] CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour

asulacrine [SEP]


non-small cell lung cancer [SEP] s administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse follo


NSCLC [SEP] usion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following su


squamous carcinoma [SEP] of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveola

Carcinoma, Squamous Cell [SEP] A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium


adenocarcinoma [SEP] e of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and l

Adenocarcinoma [SEP] A malignant epithelial tumor with a glandular organization.


bronchio-alveolar carcinoma [SEP] uamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia

Adenocarcinoma, Bronchiolo-Alveolar [SEP] A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alve


undifferentiated carcinoma [SEP] d histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 1

Carcinoma [SEP] A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It i


Neutropenia [SEP] ar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infec

Neutropenia [SEP] A decrease in the number of NEUTROPHILS found in the blood.


infections [SEP] penia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade

Infection [SEP] Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.


seizures [SEP] en in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting

Seizures [SEP] Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of br


nausea [SEP]  grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infus

Nausea [SEP] An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and moti


vomiting [SEP] seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37

Vomiting [SEP] The forcible expulsion of the contents of the STOMACH through the MOUTH.


phlebitis [SEP] n or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcin

Phlebitis [SEP] Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).


squamous cell carcinoma [SEP] ourses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months. Further testing i


tumour [SEP] xamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluabl

Neoplasms [SEP] New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and me


Alpha-lipoic acid [SEP] Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental

Thioctic Acid [SEP] An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is bio


mitochondrial damage [SEP] Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.

Mitochondrial Diseases [SEP] Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondri


neurotoxicity [SEP] Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.

Neurotoxicity Syndromes [SEP] Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method


neuropathy [SEP] chondrial damage and neurotoxicity in experimental chemotherapy neuropathy.

Nervous System Diseases [SEP] Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, periph


alpha-lipoic acid [SEP] The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity,


neurotoxicity [SEP] pha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurode


mitochondrial damage [SEP]  neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and i


toxic neurodegenerative cascade [SEP] neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on

Nerve Degeneration [SEP] Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction o


peripheral neuropathy [SEP] a protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cu

Peripheral Nervous System Diseases [SEP] Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, pl


paclitaxel [SEP] imary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherap

Paclitaxel [SEP] A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized


cisplatin [SEP] of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs. T

Cisplatin [SEP] An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and inter


axonal damage [SEP] d investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology o

Basal Ganglia Diseases [SEP] Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (mos


mitochondrial impairment [SEP] ults demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vac


Alpha-lipoic acid [SEP] rane potential and induction of autophagic vacuoles in neurons. Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neu


mitochondrial toxicity [SEP] herapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondr


peripheral nerve toxicity [SEP] gest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confi


stroke [SEP] Optimising stroke prevention in non-valvular atrial fibrillation.

Stroke [SEP] A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA o


atrial fibrillation [SEP] Optimising stroke prevention in non-valvular atrial fibrillation.

Atrial Fibrillation [SEP] Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the


Atrial fibrillation [SEP] Atrial fibrillation is associated with substantial morbidity and mortality. Pooled


warfarin [SEP] comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduc

Warfarin [SEP] An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the


stroke [SEP] tment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%. Overall


aspirin [SEP] shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%. Overall, in high-risk patients,

Aspirin [SEP] The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties a


strokes [SEP] gh-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%. Ximelagatran, an oral d


Ximelagatran [SEP] n in preventing strokes, with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficien

ximelagatran [SEP]


vitamin K [SEP] oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has b

Vitamin K [SEP] A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phyto


embolic events [SEP] as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver func

Embolism [SEP] Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.


abnormal liver function [SEP] n of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with

Drug-Induced Liver Injury [SEP] A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug


Atrial Fibrillation [SEP] thdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Ev


Clopidogrel [SEP] bnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study

clopidogrel [SEP]


Irbesartan [SEP] tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that

irbesartan [SEP]


clopidogrel [SEP] has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux,

clopidogrel [SEP]


Idraparinux [SEP] (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atr

idraparinux [SEP]


atrial fibrillation [SEP] nux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II re


Angiotensin [SEP] bitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocki

Angiotensins [SEP] Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANG


angiotensin II [SEP] rial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation thr

Angiotensin II [SEP] An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino aci


cardiac remodelling [SEP] ptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling. Preliminary studies suggest that statins could interfere with

Ventricular Remodeling [SEP] The geometric and structural changes that the HEART VENTRICLES undergo, usually following MYOCARDIAL INFARCTION. It comprises ex


statins [SEP] n through cardiac remodelling. Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical ca

Simvastatin [SEP] A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLU


cyclosporin A [SEP] Interaction of cyclosporin A with antineoplastic agents.

Cyclosporine [SEP] A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes.


etoposide [SEP] A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lympho

Etoposide [SEP] A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a co


cyclosporin A [SEP] A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in


acute T-lymphocytic leukemia [SEP] t of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse. The concomitant administration of etoposide and cyc

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma [SEP] A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvem


leukemic infiltration [SEP] nd cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental confusio

Leukemic Infiltration [SEP] A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukem


confusion [SEP] ltration of bone marrow. Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhanc

Confusion [SEP] A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.


hyperbilirubinemia [SEP] evere side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic ef

Hyperbilirubinemia [SEP] A condition characterized by an abnormal increase of BILIRUBIN in the blood, which may result in JAUNDICE. Bilirubin, a breakdow


toxicity [SEP] o an enhancement not only of antineoplastic effects but also of toxicity in normal tissues. This report demonstrates for the first time

Drug-Related Side Effects and Adverse Reactions [SEP] Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chem


cefonicid [SEP] The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin h

Cefonicid [SEP] A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition


cefazedone [SEP] The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity i

cefazedone [SEP]


cephalosporin [SEP] ts of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.

Cephalosporins [SEP] A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moie


hematotoxicity [SEP] d and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.

Hematologic Diseases [SEP] Disorders of the blood and blood forming tissues.


Cephalosporin [SEP] Cephalosporin antibiotics cause a variety of hematologic disturbances in man,


hematologic disturbances [SEP] Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain po


blood dyscrasias [SEP]  There is a need for a well-defined animal model in which these blood dyscrasias can be studied. In four subacute toxicity studies, the intraven


toxicity [SEP] n which these blood dyscrasias can be studied. In four subacute toxicity studies, the intravenous administration of cefonicid or cefazed


cefonicid [SEP] ur subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence


cefazedone [SEP] oxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neu

cefazedone [SEP]